An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning

Metabolic syndrome (MetS) is a clustering of several cardiovascular risk factors that include: obesity, dyslipidemia, hypertension and high blood glucose, and often requires multidrug pharmacological interventions. The management of MetS therefore requires high healthcare cost, and can result in poo...

Descripción completa

Detalles Bibliográficos
Autores principales: Rameshrad, Maryam, Razavi, Bibi Marjan, Lalau, Jean-Daniel, De Broe, Marc E., Hosseinzadeh, Hossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mashhad University of Medical Sciences 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374997/
https://www.ncbi.nlm.nih.gov/pubmed/32742592
http://dx.doi.org/10.22038/ijbms.2020.41638.9832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374997/
https://www.ncbi.nlm.nih.gov/pubmed/32742592
http://dx.doi.org/10.22038/ijbms.2020.41638.9832

Ejemplares similares